Cytokeratin 5 Antibody KRT5/3594 / CK5 Monoclonal Antibody [clone KRT5/3594] (V7568)

Cytokeratin 5 Antibody KRT5/3594 by IHC in Human Prostate Carcinoma. Immunohistochemistry of FFPE human prostate carcinoma tissue using Cytokeratin 5 Antibody KRT5/3594. Strong brown DAB staining is observed predominantly along the epithelial lining of glandular structures, with relatively little staining in the surrounding stromal tissue. The CK5 Monoclonal Antibody highlights epithelial cell populations surrounding glandular lumens, consistent with the association of KRT5 with basal epithelial differentiation. Nuclei are counterstained blue with hematoxylin. Heat-induced epitope retrieval was performed by boiling tissue sections in 10 mM citrate buffer, pH 6, for 10-20 minutes.

Cytokeratin 5 Antibody KRT5/3594 by IHC in Human Prostate Carcinoma, Second View. Immunohistochemistry of FFPE human prostate carcinoma tissue using Cytokeratin 5 Antibody KRT5/3594. Brown DAB staining is concentrated along the peripheral epithelial layers of multiple glandular structures, while the central luminal regions and surrounding stromal tissue exhibit comparatively little staining. The CK5 Monoclonal Antibody produces a predominantly cytoplasmic staining pattern within the epithelial compartment. Nuclei are counterstained blue with hematoxylin. Heat-induced epitope retrieval was performed using 10 mM citrate buffer, pH 6, for 10-20 minutes.

Cytokeratin 5 Antibody KRT5/3594 by IHC in Human Cervical Carcinoma. Immunohistochemistry of FFPE human cervical carcinoma tissue using Cytokeratin 5 Antibody KRT5/3594. Strong brown DAB staining is observed throughout the cytoplasm of numerous tumor cells exhibiting squamous morphology. The staining highlights epithelial tumor nests and individual carcinoma cells, while adjacent connective tissue shows considerably weaker staining. The CK5 Monoclonal Antibody demonstrates the association of KRT5 expression with squamous epithelial differentiation. Nuclei are counterstained blue with hematoxylin. Heat-induced epitope retrieval was performed using 10 mM citrate buffer, pH 6, for 10-20 minutes.

Cytokeratin 5 Antibody KRT5/3594 by IHC in Human Pancreas. Immunohistochemistry of FFPE human pancreatic tissue using Cytokeratin 5 Antibody KRT5/3594. Widespread brown DAB staining is observed in the cytoplasm of numerous cells throughout the tissue, with variable staining intensity and relatively little staining in intervening connective tissue. The CK5 Monoclonal Antibody demonstrates immunoreactivity in this pancreatic specimen, although the extensive staining should not be interpreted as evidence of the normal physiological distribution of KRT5 without additional validation. Nuclei are counterstained blue with hematoxylin. Heat-induced epitope retrieval was performed using 10 mM citrate buffer, pH 6, for 10-20 minutes.

Cytokeratin 5 Antibody KRT5/3594 by SDS-PAGE. SDS-PAGE analysis of purified, BSA-free Cytokeratin 5 Antibody KRT5/3594 under reducing (R) and non-reducing (NR) conditions, with 2 ug of antibody loaded per lane. The non-reducing lane shows a prominent band migrating at approximately 150 kDa, consistent with intact IgG. Under reducing conditions, distinct bands are observed at approximately 50 kDa and 25 kDa, corresponding to the expected immunoglobulin heavy and light chains, respectively. The electrophoretic profile is consistent with the expected composition of a purified mouse monoclonal antibody preparation.

Cytokeratin 5 Antibody KRT5/3594 by Protein Microarray. Protein microarray specificity analysis of Cytokeratin 5 Antibody KRT5/3594 using a HuProt human protein microarray containing more than 19,000 full-length proteins. KRT5 is identified as the highest-ranking target, with a strong binding signal substantially exceeding those of most other proteins on the array. The graph displays ranked protein signals and associated Z-score and S-score measurements. The CK5 Monoclonal Antibody demonstrates preferential recognition of KRT5 under the microarray assay conditions, supporting its target specificity.